Cytosolic perfluorocarbon delivery to platelets via albumin for antithrombotic therapy

Liu, Luo; Zhong, Changqing; Gong, Tong; Ye, Qingsong; Li, Hao; Guo, Yunfei; Wen, Jinsheng; Hu, Yiqiao; Wu, Jinhui

doi:10.1016/j.jconrel.2023.01.036

Cited by 4 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In widespread, PFCs are well-tolerated when utilized as a blood alternate (Abutarboush et al, 2016), although some studies have reported toxicity or adverse immune reactions in-vitro models (Menz et al, 2018). In the duration of oxygen delivery, PFCbased emulsions are effective in improving oxygenation in animals with lung injury or hypoxia (Liu et al, 2022;Luo et al, 2023). Nevertheless, the long-term safety and efficacy of PFC-based oxygen carriers have not been comprehensively confirmed (Alayash, 2014;Charbe et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Perfluorocarbons: A perspective of theranostic applications and challenges

Kakaei

Amirian

Azadi

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Perfluorocarbon (PFC) are biocompatible compounds, chemically and biologically inert, and lacks toxicity as oxygen carriers. PFCs nanoemulsions and nanoparticles (NPs) are highly used in diagnostic imaging and enable novel imaging technology in clinical imaging modalities to notice and image pathological and physiological alterations. Therapeutics with PFCs such as the innovative approach to preventing thrombus formation, PFC nanodroplets utilized in ultrasonic medication delivery in arthritis, or PFC-based NPs such as Perfluortributylamine (PFTBA), Pentafluorophenyl (PFP), Perfluorohexan (PFH), Perfluorooctyl bromide (PFOB), and others, recently become renowned for oxygenating tumors and enhancing the effects of anticancer treatments as oxygen carriers for tumor hypoxia. In this review, we will discuss the recent advancements that have been made in PFC’s applications in theranostic (therapeutics and diagnostics) as well as assess the benefits and drawbacks of these applications.

show abstract

Section: Introductionmentioning

confidence: 99%

Perfluorocarbons: A perspective of theranostic applications and challenges

Kakaei

Amirian

Azadi

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…1,2 PFCs have found widespread utility as components of medical devices, drug delivery vehicles, and sensors. 3,4,5 As the use of PFCs has grown, so has the array of fluorophores that can be employed to label the fluorous phase. We have deemed these fluorophores "fluorofluorophores" where the first "fluoro" refers to fluorine and the second refers to fluorescence.…”

mentioning

confidence: 99%

Counterion Exchange Enhances the Brightness and Photostability of a Fluorous Cyanine Dye

Lin,

Lim,

Sletten

2024

Preprint

View full text Add to dashboard Cite

show abstract

A Hybrid Nanoadjuvant Simultaneously Depresses PD‐L1/TGF‐β1 and Activates cGAS‐STING Pathway to Overcome Radio‐Immunotherapy Resistance

Yi,

Jiang,

Zhou

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

Currently, certain cancer patients exhibit resistance to radiotherapy due to reduced DNA damage under hypoxic conditions and acquired immune tolerance triggered by transforming growth factor‐β1 (TGF‐β1) and membrane‐localized programmed death ligand‐1 (PD‐L1). Meanwhile, cytoplasm‐distributed PD‐L1 induces radiotherapy resistance through accelerating DNA damage repair (DDR). However, the disability of clinically used PD‐L1 antibodies in inhibiting cytoplasm‐distributed PD‐L1 limited their effectiveness. Therefore, we developed a nanoadjuvant to sensitize cancer to radiotherapy via multi‐level immunity activation through depressing PD‐L1 and TGF‐β1 by Triphenylphosphine‐derived Metformin (Tpp‐Met), and activating the cGAS‐STING pathway by generating Mn2+ from MnO2 and producing more dsDNA via reversing tumor hypoxia and impairing DDR. Thus, Tpp‐Met@MnO2@Alb effectively enhanced the efficiency of radiotherapy to inhibit the progression of irradiated local and abscopal tumors and tumor lung metastases, offering a long‐term memory of antitumor immunity without discernible side effects. Overall, Tpp‐Met@MnO2@Alb had the potential to be clinically applied for overcoming radio‐immunotherapy resistance.This article is protected by copyright. All rights reserved

show abstract

Cytosolic perfluorocarbon delivery to platelets via albumin for antithrombotic therapy

Cited by 4 publications

References 35 publications

Perfluorocarbons: A perspective of theranostic applications and challenges

Perfluorocarbons: A perspective of theranostic applications and challenges

Counterion Exchange Enhances the Brightness and Photostability of a Fluorous Cyanine Dye

A Hybrid Nanoadjuvant Simultaneously Depresses PD‐L1/TGF‐β1 and Activates cGAS‐STING Pathway to Overcome Radio‐Immunotherapy Resistance

Contact Info

Product

Resources

About